TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report published on Friday morning. The firm issued a hold rating on the stock.

TherapeuticsMD Stock Performance

TXMD stock opened at $1.40 on Friday. TherapeuticsMD has a 1-year low of $1.36 and a 1-year high of $3.07. The business has a fifty day moving average price of $1.61 and a 200-day moving average price of $1.78.

Institutional Trading of TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP boosted its position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 636,622 shares of the company’s stock after acquiring an additional 101,282 shares during the quarter. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent reporting period. 30.74% of the stock is owned by hedge funds and other institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.